Business
CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions - SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)-- Second
About this update from Veracyte, Inc.
[{"type":"text","content":"\n- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions -\n\n SOUTH SAN FRANCISCO, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--\nSecond paragraph, first sentence of release should include Dr. Jose Herazo-Maya, currently Director of Interstitial Lung Disease Program NCH Healthcare System, Naples, Fla.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005227/en/\n\nThe corrected release reads:\n\n\nVERACYTE AND YALE ANNOUNCE EXCLUSIVE LICENSE TO ADVANCE FIRST GENOMIC MONITORING TEST FOR IDIOPATHIC PULMONARY FIBROSIS\n\n\n- Non-Invasive, Blood-Based Test Could Help Inform Key Treatment Decisions -\n\n\nVeracyte, Inc. (Nasdaq: VCYT) and Yale University today announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF). The agreement gives Veracyte rights to a 52-gene signature developed by Yale researchers, for use on the nCounter FLEX Analysis System – Veracyte’s exclusively licensed diagnostics platform. Veracyte plans to make the non-invasive, blood-based test available as a complement to its Envisia Genomic Classifier, as part of a comprehensive offering to aid in the diagnosis and treatment of patients with IPF.\n\n\nThe 52-gene signature in peripheral blood, developed by Dr. Naftali Kaminski, chief of the Section of Pulmonary, Critical Care and Sleep Medicine in the Department of Medicine at Yale University’s School of Medicine, Dr. Jose Herazo-Maya, currently Director of Interstitial Lung Disease Program NCH Healthcare System, Naples, Fla. and collaborators*, is shown to predict rapid disease progression among patients with IPF. In a study published in Science Translational Medicine, the genomic profile was substantially more accurate at identifying patients with poor outcomes as compared to a traditional assessment using clinical variables. The findings were subsequently validated in an international multicenter study published in Lancet Respiratory Medicine. \n\n\n“We are excited to advance groundbreaking research from Dr. Kaminski and his team into a commercially available, first-of-its-kind genomic test that may further help guide care for patients with IPF,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “The ...